Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Am J Physiol Renal Physiol ; 308(1): F69-75, 2015 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-25377911

RESUMEN

Previous studies have indicated that macrophage phenotype diversity is involved in the progression of renal fibrosis. However, the factors facilitating M1 or M2 phenotypes and the function of these polarized macrophages in kidney injury and fibrosis remain largely unknown. In the present study, we found that macrophages accumulated in the kidney interstitium exhibited mainly as the M1 phenotype at the early stage of unilateral ureter obstruction (UUO). High-mobility group box 1 (HMGB1) protein expressed and released from tubular epithelial cells and interstitial macrophages was essential for the M1 macrophage transition. HMGB1 significantly induced the expression of the M1 marker inducible nitric oxide synthase while decreasing the M2 marker IL-10 in macrophages. Moreover, a glycyrrhizic acid derivative, a blocker of HMGB1 release, reduced UUO-mediated kidney injury and ameliorated UUO-induced renal fibrosis. Interestingly and importantly, UUO caused a low pH value in the urine accumulated in the obstructed ureter, and the acidified urine induced HMGB1 release from tubular epithelial cells and macrophages in vitro. Our data demonstrate that HMGB1 is an essential contributor in facilitating M1 polarization at the early stage of UUO. Inhibition of HMGB1 release may alter macrophage phenotype and contribute to the protection of kidney tissue from injury and fibrosis.


Asunto(s)
Proteína HMGB1/metabolismo , Macrófagos/fisiología , Nefroesclerosis/inmunología , Obstrucción Ureteral/inmunología , Animales , Células Cultivadas , Evaluación Preclínica de Medicamentos , Ácido Glicirrínico/farmacología , Ácido Glicirrínico/uso terapéutico , Proteína HMGB1/antagonistas & inhibidores , Humanos , Masculino , Ratones Endogámicos C57BL , Nefroesclerosis/tratamiento farmacológico , Nefroesclerosis/metabolismo , Fenotipo , Fitoterapia , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Obstrucción Ureteral/complicaciones , Obstrucción Ureteral/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...